David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

PLTR Stock Alert: The $100 Million Reason Palantir Is Rising Today

By David Moadel, InvestorPlace Contributor

PLTR stock traders are cheering Palantir's new contract with the U.S. government as it will provide a major revenue source.

Why You Can’t Count on a Comeback for NIO Stock

By David Moadel, InvestorPlace Contributor

NIO stock will probably stay in the slow lane for a while as Nio over-spends and posts some troubling financial figures.

Lucid Outlook: How Much Further Could LCID Stock Fall?

By David Moadel, InvestorPlace Contributor

LCID stock is on shaky ground in 2023 as the demand for Lucid Group's vehicles remains weak and a $7,500 credit probably won't help much.

Atlassian Layoffs 2023: What to Know About the Latest TEAM Job Cuts

By David Moadel, InvestorPlace Contributor

A report of Atlassian layoffs is circulating right now. TEAM stock traders don't seem too bothered about the news, however.

Why Is Virax Biolabs (VRAX) Stock Up 100% Today?

By David Moadel, InvestorPlace Contributor

Virax Biolabs just announced a new testing kit for a potentially deadly disease in Europe, and VRAX stock traders are on a buying spree.

Why You Should Invest $100 in Rivian (RIVN) Stock Now

By David Moadel, InvestorPlace Contributor

It's hard to go wrong with a $100 stake in RIVN stock as Wall Street's experts brace for epic share-price appreciation.

Lordstown Motors Outlook: Don’t Count on a Comeback for RIDE Stock

By David Moadel, InvestorPlace Contributor

RIDE stock probably won't ride higher anytime soon as financial traders assess Lordstown Motors' vehicle recall and production halt.

RACE Stock Alert: Ferrari Beats Out Tesla as Morgan Stanley’s Top Auto Stock

By David Moadel, InvestorPlace Contributor

RACE stock could gain traction today as a notable Wall Street expert surprisingly picks Ferrari over Tesla.

C3.ai Outlook: Where Will AI Stock Be in 5 Years?

By David Moadel, InvestorPlace Contributor

The surge in AI stock may, in part, be attributable to short covering. Nonetheless, C3.ai's shareholders should enjoy strong multi-year gains.

Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today?

By David Moadel, InvestorPlace Contributor

BBIO stock looks unstoppable today as BridgeBio Pharma diligently advances a treatment for a rare and unfortunate condition.

Load More